Pharmafile Logo
Pharmafocus logo
Advanced Search
regeneron

Regeneron to invest $350 million, create 200 jobs in Ireland

October 19, 2015
Manufacturing and Production, Research and Development

US pharma company Regeneron has announced plans to invest $350 million into its production facility in Limerick, Ireland, creating 200 …

News
Allergan

2015’s top five mergers and acquisitions in a record-breaking year

October 19, 2015
Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers

A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …

Feature
Flemming Ornskov

Shire’s dry eye treatment gets a no – for now

October 19, 2015
Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …

News
BI building at night

FDA approves Boehringer’s Pradaxa reversal agent

October 19, 2015
Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …

News
Praluent

Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015
Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …

News
onglyza

FDA rejects AstraZeneca diabetes combination

October 16, 2015
Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin

The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …

News
pfizer_logo

Pfizer’s Xeljanz denied plaque psoriasis indication by FDA

October 16, 2015
Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib

The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …

News
abbvies_humira_cost_the_most_to_market_in_the_us_last_month

Top 10 US pharma advertising spenders, September 2015

October 16, 2015
Medical Communications, Sales and Marketing

 As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …

Feature

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
david_tweedale_and_ian_robinson

Ashfield UK makes two new business development appointments for its growing team

October 16, 2015
Medical Communications Ashfield UK

Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located …

Appointment
david_mustalish

The Prime Medical Group expands senior team in New York City

October 16, 2015
Medical Communications

The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …

Appointment
texting mobile

Health apps now more popular than ever in the UK

October 16, 2015
Medical Communications apps, digital pharma, health technology, technology

The use of health apps has considerably increased over the past years, according to a new survey that has found …

News
NHS sign

NICE requests more evidence on Duchenne muscular dystrophy therapy

October 16, 2015
Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren

NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …

News

The Prime Medical Group expands senior team in New York City

October 15, 2015
Medical Communications The Prime Medical Group

The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …

News
Press release
Valeant logo

Valeant receives court writ over US drug pricing

October 15, 2015
Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena

Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …

News
T-cell

$350m collaboration deal for BMS and Five Prime Therapeutics

October 15, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

News
Ablynx flags

Ablynx and Merck begin immuno-oncology collaboration

October 15, 2015
Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept

Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …

News
allergan_ceo_bernie_saunders

Allergan axes 117 jobs in Kythera buyout

October 15, 2015
Allergan, Kythera

According to a notice filed with the state of California, Allergan will be laying off 117 employees at Kythera’s Westlake …

Appointment
PM David Cameron

ABPI hits back at Prime Minister’s criticism of high drug prices

October 15, 2015
Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease

The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …

News

Crescendo Biologics appoints Dr Peter Pack as chief exec

October 15, 2015
Business Services, Research and Development

Crescendo Biologics has announced the appointment of Dr Peter Pack as chief executive, who will oversee the company’s new drug …

Appointment
The Gateway to Local Adoption Series

Latest content

NICE backs atogepant for acute migraine treatment

June 12, 2026

Survey data highlight challenges in anaphylaxis treatment adherence

June 11, 2026

Hansa Biopharma appoints Fredrik Röök as VP Business Development

June 11, 2026

Sofinnova and AWS collaborate on AI tools for life sciences

June 10, 2026

First European approval given to non-opioid treatment for chronic low back pain

June 9, 2026